Quick Update: Radient Pharmaceuticals (RPC)

On 4/20/10, I posted a Quick Analysis on Radient Pharmaceuticals (RPC). (Click HERE if you would like to see that analysis.)

There is one change really worth noting:

They have supporting data indicating that their still-in-testing (not in production) drug Onko-Sure, a drug that helps detect breast cancer in women by a simple blood test and at an early stage, is effective.

This drug is only in Phase 1 of its FDA testing. So it has to travel a rigorous route, but the data makes me rate this as a speculative stock purchase, still, but it offers a much better chance of seeing its upside than I thought it did when I wrote my analysis originally.

This is still not any sort of guarantee. This company does not generate anything close to a profit, but this drug would have a tremendous market if and when it does pass all of the FDA testing.

Here is an article that details things a little better: Click HERE for the article.